Proteus and Otsuka to develop novel digital health products

Friday, July 6, 2012 11:24 AM

Proteus Digital Health, developer of wearable and ingestible sensor technology, and Otsuka Pharmaceutical, a global healthcare company based in Japan, have entered into an exclusive worldwide license and collaboration agreement to develop and commercialize a new category of medicines.

These new medicines will be based on Otsuka’s pharmaceutical products and Proteus’s digital health feedback system incorporating Proteus’s novel sensor-based technologies. The duo will develop commercial products in two defined therapeutic areas of high unmet medical need. Otsuka has also been granted a non-exclusive license to utilize Proteus technology in its clinical research and development activities.

Financial terms of the agreement were not disclosed.

Share:          
CWWeekly

January 19

Roche takes $1B majority stake in Foundation Medicine to use genomic testing to personalize oncology treatments

BRANY launches software, iPad app to streamline protocol creation for investigator-initiated trials

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January

All eyes on EMA’s adaptive licensing pilot
Sponsors could offer innovative drugs to patients 8 years sooner

Ice Bucket Challenge a boon for ALS research
Donations soar, but phenomenon difficult to replicate

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

December

Growing adoption of feasibility review committees
Early reports cite fewer amendments, improved cycle time

AMCs vying to better compete for industry trials
Working to conquer study start-up delays, IRB review process

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs